JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB226777

Anti-HLA DRB5 antibody

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Polyclonal HLA DRB5 antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human HLA class II histocompatibility antigen, DR beta 5 chain.

View Alternative Names

DR beta-5, DR2-beta-2, Dw2, MHC class II antigen DRB5, HLA-DRB5

1 Images
Western blot - Anti-HLA DRB5 antibody (AB226777)
  • WB

Supplier Data

Western blot - Anti-HLA DRB5 antibody (AB226777)

12% SDS-PAGE gel.

All lanes:

Western blot - Anti-HLA DRB5 antibody (ab226777) at 1/5000 dilution

Lane 1:

Raji (human Burkitt's lymphoma cell line) whole cell extract at 30 µg

Lane 2:

Raji (human Burkitt's lymphoma cell line) membrane extract at 30 µg

Predicted band size: 30 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

Synthetic Peptide within Human HLA class II histocompatibility antigen, DR beta 5 chain. The exact immunogen used to generate this antibody is proprietary information.

Q30154

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7 Preservative: 0.025% Proclin 300 Constituents: PBS, 20% Glycerol (glycerin, glycerine)
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
See full target information HLA class II histocompatibility antigen, DR beta 5 chain

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Oncogenesis 7:84 PubMed30420689

2018

Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia.

Applications

Unspecified application

Species

Unspecified reactive species

Zheng Ge,Qi Han,Yan Gu,Qinyu Ge,Jinlong Ma,Justin Sloane,Guofeng Gao,Kimberly J Payne,Laszlo Szekely,Chunhua Song,Sinisa Dovat
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com